Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010
MenAfriVac is a new conjugate vaccine against Neisseria meningitidis serogroup A developed for the African "meningitis belt". In Niger, the first two phases of the MenAfriVac introduction campaign were conducted targeting 3,135,942 individuals aged 1 to 29 years in the regions of Tillabéri...
Gespeichert in:
| Veröffentlicht in: | PloS one 2012-01, Vol.7 (1), p.e29116-e29116 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e29116 |
|---|---|
| container_issue | 1 |
| container_start_page | e29116 |
| container_title | PloS one |
| container_volume | 7 |
| creator | Kim, Sung Hye Pezzoli, Lorenzo Yacouba, Harouna Coulibaly, Tiekoura Djingarey, Mamoudou H Perea, William A Wierzba, Thomas F |
| description | MenAfriVac is a new conjugate vaccine against Neisseria meningitidis serogroup A developed for the African "meningitis belt". In Niger, the first two phases of the MenAfriVac introduction campaign were conducted targeting 3,135,942 individuals aged 1 to 29 years in the regions of Tillabéri, Niamey, and Dosso, in September and December 2010. We evaluated the campaign and determined which sub-populations or areas had low levels of vaccination coverage in the regions of Tillabéri and Niamey. After Phase I, conducted in the Filingué district, we estimated coverage using a 30×15 cluster-sampling survey and nested lot quality assurance (LQA) analysis in the clustered samples to identify which subpopulations (defined by age 1-14/15-29 and sex) had unacceptable vaccination coverage ( |
| doi_str_mv | 10.1371/journal.pone.0029116 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1323090160</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A477056937</galeid><doaj_id>oai_doaj_org_article_5a8724906afc4791860a103b641567e1</doaj_id><sourcerecordid>A477056937</sourcerecordid><originalsourceid>FETCH-LOGICAL-c691t-11d0ea0c918648a44aad92834e23c1e1d8392326710b4c8bb8d80063d30ed8583</originalsourceid><addsrcrecordid>eNqNk12LEzEUhgdR3HX1H4gGBMWL1nxMMzM3Sil-FBYX_LwMp5kz05RpUpNMq__Cn2xqZ5dW9kJCSEie9z3JSU6WPWZ0zETBXq1c7y10442zOKaUV4zJO9k5qwQfSU7F3aP5WfYghBWlE1FKeT8745wXktH8PPv9fenWBGxNdkv0SCD1HRLrItmC1sZCNLZ9Q2Zuix7aBDQRPYlLJMZG7-peR-MscQ0BYnFHtLOrvoWIgz4pWjA2RNJ612_IlKzRJkunndZ9SC7ko2mTZZpwyujD7F4DXcBHw3iRfX339svsw-jy6v18Nr0caVmxOGKspghUV6yUeQl5DlBXvBQ5cqEZsroUFRdcFowucl0uFmVdUipFLSjW5aQUF9nTg--mc0ENyQyKCS5oRZmkiZgfiNrBSm28WYP_pRwY9XfB-VaBj0Z3qCZQFjyvqIRG58X-TBQYFQuZs4kskCWv10O0frHGWmPKHXQnpqc71ixV67YqXYEXJU8GLwYD7370GKJam6Cx68Ci64NKMamY0KJK5LN_yNsvN1AtpPMb27gUVu891TQvCjqRlSgSNb6FSq3GtUkvjY1J6yeClyeCxET8GVvoQ1Dzz5_-n736dso-P2KXCF1cBtf1-78XTsH8AGrvQvDY3OSYUbWvm-tsqH3dqKFukuzJ8fvciK4LRfwBWAYRDA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1323090160</pqid></control><display><type>article</type><title>Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Kim, Sung Hye ; Pezzoli, Lorenzo ; Yacouba, Harouna ; Coulibaly, Tiekoura ; Djingarey, Mamoudou H ; Perea, William A ; Wierzba, Thomas F</creator><creatorcontrib>Kim, Sung Hye ; Pezzoli, Lorenzo ; Yacouba, Harouna ; Coulibaly, Tiekoura ; Djingarey, Mamoudou H ; Perea, William A ; Wierzba, Thomas F</creatorcontrib><description>MenAfriVac is a new conjugate vaccine against Neisseria meningitidis serogroup A developed for the African "meningitis belt". In Niger, the first two phases of the MenAfriVac introduction campaign were conducted targeting 3,135,942 individuals aged 1 to 29 years in the regions of Tillabéri, Niamey, and Dosso, in September and December 2010. We evaluated the campaign and determined which sub-populations or areas had low levels of vaccination coverage in the regions of Tillabéri and Niamey. After Phase I, conducted in the Filingué district, we estimated coverage using a 30×15 cluster-sampling survey and nested lot quality assurance (LQA) analysis in the clustered samples to identify which subpopulations (defined by age 1-14/15-29 and sex) had unacceptable vaccination coverage (<70%). After Phase II, we used Clustered Lot Quality Assurance Sampling (CLQAS) to assess if any of eight districts in Niamey and Tillabéri had unacceptable vaccination coverage (<75%) and estimated overall coverage. Estimated vaccination coverage was 77.4% (95%CI: 84.6-70.2) as documented by vaccination cards and 85.5% (95% CI: 79.7-91.2) considering verbal history of vaccination for Phase I; 81.5% (95%CI: 86.1-77.0) by card and 93.4% (95% CI: 91.0-95.9) by verbal history for Phase II. Based on vaccination cards, in Filingué, we identified both the male and female adult (age 15-29) subpopulations as not reaching 70% coverage; and we identified three (one in Tillabéri and two in Niamey) out of eight districts as not reaching 75% coverage confirmed by card. Combined use of LQA and cluster sampling was useful to estimate vaccination coverage and to identify pockets with unacceptable levels of coverage (adult population and three districts). Although overall vaccination coverage was satisfactory, we recommend continuing vaccination in the areas or sub-populations with low coverage and reinforcing the social mobilization of the adult population.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0029116</identifier><identifier>PMID: 22276104</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adolescent ; Adult ; Bacterial Vaccines - administration & dosage ; Bacterial Vaccines - immunology ; Biology ; Child ; Child, Preschool ; Clusters ; Estimates ; Evaluation ; Female ; Humans ; Infant ; Male ; Malnutrition ; Medicine ; Meningitis ; Neisseria meningitidis, Serogroup A - immunology ; Niger ; Poliomyelitis ; Populations ; Pregnancy ; Quality assurance ; Quality control ; Sampling ; Subpopulations ; Vaccination ; Vaccination - statistics & numerical data ; Vaccines ; Vaccines, Conjugate - administration & dosage ; Vaccines, Conjugate - immunology ; Young Adult</subject><ispartof>PloS one, 2012-01, Vol.7 (1), p.e29116-e29116</ispartof><rights>COPYRIGHT 2012 Public Library of Science</rights><rights>2012 Kim et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Kim et al. 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c691t-11d0ea0c918648a44aad92834e23c1e1d8392326710b4c8bb8d80063d30ed8583</citedby><cites>FETCH-LOGICAL-c691t-11d0ea0c918648a44aad92834e23c1e1d8392326710b4c8bb8d80063d30ed8583</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262782/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262782/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79342,79343</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22276104$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Sung Hye</creatorcontrib><creatorcontrib>Pezzoli, Lorenzo</creatorcontrib><creatorcontrib>Yacouba, Harouna</creatorcontrib><creatorcontrib>Coulibaly, Tiekoura</creatorcontrib><creatorcontrib>Djingarey, Mamoudou H</creatorcontrib><creatorcontrib>Perea, William A</creatorcontrib><creatorcontrib>Wierzba, Thomas F</creatorcontrib><title>Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>MenAfriVac is a new conjugate vaccine against Neisseria meningitidis serogroup A developed for the African "meningitis belt". In Niger, the first two phases of the MenAfriVac introduction campaign were conducted targeting 3,135,942 individuals aged 1 to 29 years in the regions of Tillabéri, Niamey, and Dosso, in September and December 2010. We evaluated the campaign and determined which sub-populations or areas had low levels of vaccination coverage in the regions of Tillabéri and Niamey. After Phase I, conducted in the Filingué district, we estimated coverage using a 30×15 cluster-sampling survey and nested lot quality assurance (LQA) analysis in the clustered samples to identify which subpopulations (defined by age 1-14/15-29 and sex) had unacceptable vaccination coverage (<70%). After Phase II, we used Clustered Lot Quality Assurance Sampling (CLQAS) to assess if any of eight districts in Niamey and Tillabéri had unacceptable vaccination coverage (<75%) and estimated overall coverage. Estimated vaccination coverage was 77.4% (95%CI: 84.6-70.2) as documented by vaccination cards and 85.5% (95% CI: 79.7-91.2) considering verbal history of vaccination for Phase I; 81.5% (95%CI: 86.1-77.0) by card and 93.4% (95% CI: 91.0-95.9) by verbal history for Phase II. Based on vaccination cards, in Filingué, we identified both the male and female adult (age 15-29) subpopulations as not reaching 70% coverage; and we identified three (one in Tillabéri and two in Niamey) out of eight districts as not reaching 75% coverage confirmed by card. Combined use of LQA and cluster sampling was useful to estimate vaccination coverage and to identify pockets with unacceptable levels of coverage (adult population and three districts). Although overall vaccination coverage was satisfactory, we recommend continuing vaccination in the areas or sub-populations with low coverage and reinforcing the social mobilization of the adult population.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Bacterial Vaccines - administration & dosage</subject><subject>Bacterial Vaccines - immunology</subject><subject>Biology</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Clusters</subject><subject>Estimates</subject><subject>Evaluation</subject><subject>Female</subject><subject>Humans</subject><subject>Infant</subject><subject>Male</subject><subject>Malnutrition</subject><subject>Medicine</subject><subject>Meningitis</subject><subject>Neisseria meningitidis, Serogroup A - immunology</subject><subject>Niger</subject><subject>Poliomyelitis</subject><subject>Populations</subject><subject>Pregnancy</subject><subject>Quality assurance</subject><subject>Quality control</subject><subject>Sampling</subject><subject>Subpopulations</subject><subject>Vaccination</subject><subject>Vaccination - statistics & numerical data</subject><subject>Vaccines</subject><subject>Vaccines, Conjugate - administration & dosage</subject><subject>Vaccines, Conjugate - immunology</subject><subject>Young Adult</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk12LEzEUhgdR3HX1H4gGBMWL1nxMMzM3Sil-FBYX_LwMp5kz05RpUpNMq__Cn2xqZ5dW9kJCSEie9z3JSU6WPWZ0zETBXq1c7y10442zOKaUV4zJO9k5qwQfSU7F3aP5WfYghBWlE1FKeT8745wXktH8PPv9fenWBGxNdkv0SCD1HRLrItmC1sZCNLZ9Q2Zuix7aBDQRPYlLJMZG7-peR-MscQ0BYnFHtLOrvoWIgz4pWjA2RNJ612_IlKzRJkunndZ9SC7ko2mTZZpwyujD7F4DXcBHw3iRfX339svsw-jy6v18Nr0caVmxOGKspghUV6yUeQl5DlBXvBQ5cqEZsroUFRdcFowucl0uFmVdUipFLSjW5aQUF9nTg--mc0ENyQyKCS5oRZmkiZgfiNrBSm28WYP_pRwY9XfB-VaBj0Z3qCZQFjyvqIRG58X-TBQYFQuZs4kskCWv10O0frHGWmPKHXQnpqc71ixV67YqXYEXJU8GLwYD7370GKJam6Cx68Ci64NKMamY0KJK5LN_yNsvN1AtpPMb27gUVu891TQvCjqRlSgSNb6FSq3GtUkvjY1J6yeClyeCxET8GVvoQ1Dzz5_-n736dso-P2KXCF1cBtf1-78XTsH8AGrvQvDY3OSYUbWvm-tsqH3dqKFukuzJ8fvciK4LRfwBWAYRDA</recordid><startdate>20120120</startdate><enddate>20120120</enddate><creator>Kim, Sung Hye</creator><creator>Pezzoli, Lorenzo</creator><creator>Yacouba, Harouna</creator><creator>Coulibaly, Tiekoura</creator><creator>Djingarey, Mamoudou H</creator><creator>Perea, William A</creator><creator>Wierzba, Thomas F</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20120120</creationdate><title>Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010</title><author>Kim, Sung Hye ; Pezzoli, Lorenzo ; Yacouba, Harouna ; Coulibaly, Tiekoura ; Djingarey, Mamoudou H ; Perea, William A ; Wierzba, Thomas F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c691t-11d0ea0c918648a44aad92834e23c1e1d8392326710b4c8bb8d80063d30ed8583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Bacterial Vaccines - administration & dosage</topic><topic>Bacterial Vaccines - immunology</topic><topic>Biology</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Clusters</topic><topic>Estimates</topic><topic>Evaluation</topic><topic>Female</topic><topic>Humans</topic><topic>Infant</topic><topic>Male</topic><topic>Malnutrition</topic><topic>Medicine</topic><topic>Meningitis</topic><topic>Neisseria meningitidis, Serogroup A - immunology</topic><topic>Niger</topic><topic>Poliomyelitis</topic><topic>Populations</topic><topic>Pregnancy</topic><topic>Quality assurance</topic><topic>Quality control</topic><topic>Sampling</topic><topic>Subpopulations</topic><topic>Vaccination</topic><topic>Vaccination - statistics & numerical data</topic><topic>Vaccines</topic><topic>Vaccines, Conjugate - administration & dosage</topic><topic>Vaccines, Conjugate - immunology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Sung Hye</creatorcontrib><creatorcontrib>Pezzoli, Lorenzo</creatorcontrib><creatorcontrib>Yacouba, Harouna</creatorcontrib><creatorcontrib>Coulibaly, Tiekoura</creatorcontrib><creatorcontrib>Djingarey, Mamoudou H</creatorcontrib><creatorcontrib>Perea, William A</creatorcontrib><creatorcontrib>Wierzba, Thomas F</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Sung Hye</au><au>Pezzoli, Lorenzo</au><au>Yacouba, Harouna</au><au>Coulibaly, Tiekoura</au><au>Djingarey, Mamoudou H</au><au>Perea, William A</au><au>Wierzba, Thomas F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2012-01-20</date><risdate>2012</risdate><volume>7</volume><issue>1</issue><spage>e29116</spage><epage>e29116</epage><pages>e29116-e29116</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>MenAfriVac is a new conjugate vaccine against Neisseria meningitidis serogroup A developed for the African "meningitis belt". In Niger, the first two phases of the MenAfriVac introduction campaign were conducted targeting 3,135,942 individuals aged 1 to 29 years in the regions of Tillabéri, Niamey, and Dosso, in September and December 2010. We evaluated the campaign and determined which sub-populations or areas had low levels of vaccination coverage in the regions of Tillabéri and Niamey. After Phase I, conducted in the Filingué district, we estimated coverage using a 30×15 cluster-sampling survey and nested lot quality assurance (LQA) analysis in the clustered samples to identify which subpopulations (defined by age 1-14/15-29 and sex) had unacceptable vaccination coverage (<70%). After Phase II, we used Clustered Lot Quality Assurance Sampling (CLQAS) to assess if any of eight districts in Niamey and Tillabéri had unacceptable vaccination coverage (<75%) and estimated overall coverage. Estimated vaccination coverage was 77.4% (95%CI: 84.6-70.2) as documented by vaccination cards and 85.5% (95% CI: 79.7-91.2) considering verbal history of vaccination for Phase I; 81.5% (95%CI: 86.1-77.0) by card and 93.4% (95% CI: 91.0-95.9) by verbal history for Phase II. Based on vaccination cards, in Filingué, we identified both the male and female adult (age 15-29) subpopulations as not reaching 70% coverage; and we identified three (one in Tillabéri and two in Niamey) out of eight districts as not reaching 75% coverage confirmed by card. Combined use of LQA and cluster sampling was useful to estimate vaccination coverage and to identify pockets with unacceptable levels of coverage (adult population and three districts). Although overall vaccination coverage was satisfactory, we recommend continuing vaccination in the areas or sub-populations with low coverage and reinforcing the social mobilization of the adult population.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>22276104</pmid><doi>10.1371/journal.pone.0029116</doi><tpages>e29116</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2012-01, Vol.7 (1), p.e29116-e29116 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1323090160 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Adolescent Adult Bacterial Vaccines - administration & dosage Bacterial Vaccines - immunology Biology Child Child, Preschool Clusters Estimates Evaluation Female Humans Infant Male Malnutrition Medicine Meningitis Neisseria meningitidis, Serogroup A - immunology Niger Poliomyelitis Populations Pregnancy Quality assurance Quality control Sampling Subpopulations Vaccination Vaccination - statistics & numerical data Vaccines Vaccines, Conjugate - administration & dosage Vaccines, Conjugate - immunology Young Adult |
| title | Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T10%3A14%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Whom%20and%20where%20are%20we%20not%20vaccinating?%20Coverage%20after%20the%20introduction%20of%20a%20new%20conjugate%20vaccine%20against%20group%20A%20meningococcus%20in%20Niger%20in%202010&rft.jtitle=PloS%20one&rft.au=Kim,%20Sung%20Hye&rft.date=2012-01-20&rft.volume=7&rft.issue=1&rft.spage=e29116&rft.epage=e29116&rft.pages=e29116-e29116&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0029116&rft_dat=%3Cgale_plos_%3EA477056937%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1323090160&rft_id=info:pmid/22276104&rft_galeid=A477056937&rft_doaj_id=oai_doaj_org_article_5a8724906afc4791860a103b641567e1&rfr_iscdi=true |